Biomarkers for the early detection of cancer: An inflammatory concept

Archives of Internal Medicine

Volumn 167, Issue 17, 2007, Pages 1822-1824

  Roy, Hemant K ^a   Khandekar, Janardan D ^b  

^a EVANSTON HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 1 ANTITRYPSIN; AMYLOID A PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CA 125 ANTIGEN; CD20 ANTIBODY; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; IMMUNOGLOBULIN A; INTERLEUKIN 11 RECEPTOR; INTERLEUKIN 23; INTERLEUKIN 8; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTATE SPECIFIC ANTIGEN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADAPTIVE IMMUNITY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER SCREENING; CARCINOGENESIS; COST; DNA DAMAGE; EARLY DIAGNOSIS; EDITORIAL; ENDOSCOPY; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HIGH RISK POPULATION; HUMAN; IMMUNE SYSTEM; INFLAMMATION; LEUKOCYTE COUNT; MORTALITY; OVARY CANCER; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTO ONCOGENE; RADIOGRAPHY; SCREENING TEST; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA; WART VIRUS;

ALPHA-FETOPROTEINS; CA-125 ANTIGEN; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; NEOPLASMS; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 34748826705     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.167.17.1822     Document Type: Editorial

References (23)

1. Srivastava S, Verma M, Henson DE. Biomarkers for early detection of colon cancer. Clin Cancer Res. 2001;7(5):1118-1126.
2. Maruvada P, Srivastava S. Joint National Cancer Institute-Food and Drug Administration workshop on research strategies, study designs, and statistical approaches to biomarker validation for cancer diagnosis and detection. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1078-1082.
3. Srivastava S. Molecular screening of cancer: the future is here. Mol Diagn Ther. 2006;10(4):221-230.
4. Kagan J, Srivastava S, Barker PE, Belinsky SA, Cairns P. Towards Clinical Application of Methylated DNA Sequences as Cancer Biomarkers: A Joint NCI's EDRN and NIST Workshop on Standards, Methods, Assays, Reagents and Tools. Cancer Res. 2007;67(10):4545-4549.
5. Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin. 2006;56(2):69-83.
6. Megraud F. A humble bacterium sweeps this year's Nobel Prize. Cell. 2005;123(6):975-976.
7. Matysiak-Budnik T, Megraud F. Helicobacter pylori infection and gastric cancer. Eur J Cancer. 2006;42(6):708-716.
8. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915-1927.
9. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004;291(5):585-590.
10. McSorley MA, Alberg AJ, Allen DS, et al. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol. 2007;109(4):933-941.
11. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7(4):256-269.
12. Borghesi L, Milcarek C. Innate versus adaptive immunity: a paradigm past its prime? Cancer Res. 2007;67(9):3989-3993.
13. Van Waes C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res. 2007;13(4):1076-1082.
14. Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol. 2007;19(2):209-216.
15. Margolis KL, Rodabough RJ, Thomson CA, Lopez AM, McTiernan A; for the Women's Health Initiative Research Group. Prospective study of leukocyte count as a predictor of incident breast, colorectal, endometrial, and lung cancer and mortality in postmenopausal women. Arch Intern Med. 2007;133(17):1837- 1844.
16. Linkov F, Lisovich A, Yurkovetsky Z, et al. Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomarkers Prev. 2007;16(1):102-107.
17. Orchekowski R, Hamelinck D, Li L, et al. Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. Cancer Res. 2005;65(23):11193-11202.
18. Song K, Hanash S. Unraveling the complex proteome for biomarker discovery in gastrointestinal and liver diseases. Gastroenterology. 2006;131(5):1375-1378.
19. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst. 2007;99(8):608-615.
20. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94(4):252-266.
21. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348(10):891-899.
22. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355(9):873-884.
23. Ying L, Hofseth LJ. An emerging role for endothelial nitric oxide synthase in chronic inflammation and cancer. Cancer Res. 2007;67(4):1407-1410.